+44 (0)1865 595230
0 Items

Parvovirus

For most healthy people, parvovirus B19 infection causes a mild, self-limiting illness which is followed by life-long immunity. Infection is common in developed countries — about 15% of pre-school children, 50% of adults, and 85% of elderly people show evidence of past infection in their blood.

 

We offer recombinant virus-like particles expressing VP2 antigen in support of research into Parvovirus biology and infection.

Parvovirus background

Parvovirus B19 (B19V) is a small non-enveloped single-stranded DNA virus. It belongs to the genus Erythroparvovirus within the Parvovirinae subfamily, and is a member of the Parvoviridae family of viruses. B19V is highly infectious and is commonly transmitted from human-to-human through infected respiratory secretions. The virus can also be transmitted through B19V infected blood products, transplant material, and from mother-to-foetus during pregnancy 1 (CDC).

B19V infection commonly occurs in childhood but can occur in some adults that have not been previously exposed to the virus. In healthy individuals, B19V causes erythema infectiosum, which is generally a mild disease that is also known as fifth disease. The disease is characterised by a facial rash, which can later appear on the trunk and limbs, and is associated with mild fever and cold-like symptoms. In some adult cases, patients may present with joint pain and swelling that can continue for several months. Other symptoms of B19V infection have been described including anaemia in immunocompromised patients, and a transient decrease in erythropoiesis in cases of sickle-cell anaemia 2 (Rogo, LD. et al).

Diagnosis of B19V infection is generally performed using enzyme-linked immunosorbent assays (ELISA) to detect B19V specific IgM or IgG antibodies in the patient’s serum. Currently there is no licenced vaccine available or specific antiviral therapy for the treatment of B19V infection.

References

  1. Centers for disease control and prevention: Parvovirus and Fifth disease
  2. Rogo, LD et. al. (2014). Human parvovirus B19: a review. Acta Virol.58:199-213.

Parvovirus Antigens

Parvovirus VP2 protein is a unique product that has been developed in response to the need for high purity, properly assembled Parvovirus antigens.

Parvovirus VP2 is produced in the form of Virus-like particles (VLP) in human cell lines using state-of-the-art expression techniques. Concentration and purification is then performed by a series of ultracentrifuge and precipitation methods which result in VLPs of exceptional quality and purity.

Questions?

Check out our FAQ section for answers to the most frequently asked questions about our website and company.

How The Native Antigen Company responds to the WHO list of priority infectious diseases

In 2015, a broad group of public health and science experts gathered in Geneva to discuss emerging infectious diseases that are likely to cause future severe epidemics and public health emergencies. Organised by the World Health Organization (WHO), their aim was to...

Native Antigen release a panel of serotype specific monoclonal antibodies

  There are four distinct serotypes of Dengue Virus circulating around the world, causing Dengue fever infection which is the most important worldwide arboviral disease. There are nearly 400 million cases of Dengue annually, and around 25% present with so called...

A silver-lining from Zika virus?

Zika virus (ZIKV) is an enveloped single stranded RNA virus. It is a member of the Flavivirus genus of the family Flaviviridae, which is transmitted to humans primarily through the bite of the Aedes aegypti mosquito. In 2015, a major outbreak of Zika virus was...

Congenital CMV – a problem ignored?

Congenital CMV infection – a serious problem that receives little attention Cytomegalovirus (CMV) is a human specific double stranded DNA virus, belonging to the Herpesviridae family. CMV is ubiquitous and CMV infection is globally widespread. The virus can be...

New Nipah Virus antigens now available from The Native Antigen Company

Infection with Nipah Virus (NiV) was first recognised in Malaysia 1998/1999, where a major outbreak occurred in pigs and humans. NiV infection is now endemic in South Asia and several outbreaks of NiV infection have been reported in India and Bangladesh. Currently an...

Get in Touch With Us

The Native Antigen Company sometimes likes to send exclusive information and offers to our customers, please let us know if you are happy to receive these

5 + 1 =

Customer Feedback